AstraZeneca scrapped plans for a £450 million UK vaccine plant after rejecting a £78 million government offer, citing ...

The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...

A global pharmaceutical company partnered with DelveInsight to create a robust and simplified solution enabling its top executives to monitor the evolving breast cancer competitive intelligence ...

That includes the recent decision to reject NHS use of AZ and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) for HER2-low ...

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStoptm for the treatment of acid reflux, a treatment field ...

In a fiercely competitive market, communications service providers (CSPs) must be nimbler than ever to earn customer loyalty. As part of its digital transformation strategy, Gamma Communications plc ( ...

A global pharmaceutical company partnered with DelveInsight to create a robust and simplified solution enabling its top executives to monitor the evolving breast cancer competitive intelligence ...

Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung cancer Recommendation based on ADRIATIC Phase III trial results which ...

Researchers have developed a computer model to help scientists identify tumor-fighting immune cells in patients with lung cancer treated with immune checkpoint inhibitors.

Fresh off a reorganization, Biogen’s research leader Jane Grogan says the biotech has to 'look outside the walls of the ...

Algiax Pharmaceuticals’ non-opioid candidate has achieved “clinically meaningful” pain reduction in a mid-stage trial of ...